Viridian Therapeutics, Inc.
VRDN
$23.03
-$0.14-0.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 71.13M | 70.92M | 70.85M | 70.79M | 305.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 71.13M | 70.92M | 70.85M | 70.79M | 305.00K |
| Cost of Revenue | 328.18M | 343.23M | 342.43M | 321.68M | 304.58M |
| Gross Profit | -257.05M | -272.31M | -271.58M | -250.89M | -304.27M |
| SG&A Expenses | 151.65M | 116.89M | 95.31M | 77.23M | 67.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 479.83M | 460.12M | 437.74M | 398.91M | 371.89M |
| Operating Income | -408.70M | -389.20M | -366.90M | -328.12M | -371.59M |
| Income Before Tax | -386.97M | -360.59M | -342.60M | -301.97M | -344.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -386.97 | -360.59 | -342.60 | -301.97 | -344.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -386.97M | -360.59M | -342.60M | -301.97M | -344.06M |
| EBIT | -408.70M | -389.20M | -366.90M | -328.12M | -371.59M |
| EBITDA | -408.23M | -388.73M | -366.44M | -327.66M | -371.10M |
| EPS Basic | -3.36 | -3.32 | -3.29 | -3.02 | -3.56 |
| Normalized Basic EPS | -2.46 | -2.50 | -2.52 | -2.33 | -2.78 |
| EPS Diluted | -3.36 | -3.32 | -3.29 | -3.02 | -3.56 |
| Normalized Diluted EPS | -2.46 | -2.50 | -2.52 | -2.33 | -2.78 |
| Average Basic Shares Outstanding | 386.26M | 359.97M | 339.10M | 324.77M | 309.41M |
| Average Diluted Shares Outstanding | 386.26M | 359.97M | 339.10M | 324.77M | 309.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |